Skip to main content
. 2020 Jan 3;2020:9818129. doi: 10.1155/2020/9818129

Table 1.

Summary of pertinent laboratory investigation results and medications used for treatment of tuberculosis and melioidosis.

Baseline results Initiation of tuberculosis treatment 2 weeks into tuberculosis treatment Initiation of treatment of melioidosis 6 weeks into treatment of melioidosis
ALT 90 U/L Rifampicin 600 mg OD ALT 253 U/L Rifampicin 600 mg OD ALT 31 U/L
AST 46 U/L Isoniazid isoniazid 300 mg OD AST 526 U/L Isoniazid isoniazid 300 mg OD AST 91 U/L
Bil 11 μmol/L Ethambutol 900 mg OD Bil 90.7 μmol/L Ethambutol 900 mg OD Bil 15.7 μmol/L
ALP 444 U/L Pyrazinamide 1.5 g OD ALP 444 U/L Ceftazidime 2 g Q8H ALP 56 U/L
Creat 147 μmol/L Creat 99 μmol/L Creat 157 μmol/L
Hb 14.4 g/dl Hb 14.2 g/dl Hb 10.8 g/dl
WBC 10.88 × 109/L WBC 8.0 × 109/L WBC 1.1 × 109/L
Plt 298 × 109/L Plt 206 × 109/L Plt 217 × 109/L

Hemoglobin (Hb) 13–17 g/dL, white blood cell count (WBC) 4–10 × 103/μL, platelet (Plt) 150–450 × 103/μL, creatinine (Creat) 65–125 μmol/L, alanine transaminase (ALT) 10–55 U/L, aspartate transaminase (AST) 10–45 U/L, bilirubin (Bil) 5.0–30.0 μmol/L, albumin (Alb) 37–51 g/dL, alkaline phosphatase (ALP) 32–103 U/L, and once daily (OD).